Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved standalone treatment for this condition.

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural prayer service held for President Trump. “The person giving this sermon should be added to the deportation list,” Collins wrote in a post on the social platform X, alongside a clip of Budde’s comments. Trump has…

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.